Scarica l'app Stockscreener
14.18
5.34%
-0.80
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MYGN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$14.98
Aprire:
$15.13
Volume 24 ore:
866.71K
Relative Volume:
0.86
Capitalizzazione di mercato:
$1.29B
Reddito:
$823.60M
Utile/perdita netta:
$-116.00M
Rapporto P/E:
-10.91
EPS:
-1.3
Flusso di cassa netto:
$-107.30M
1 W Prestazione:
-2.61%
1M Prestazione:
+12.81%
6M Prestazione:
-49.23%
1 anno Prestazione:
-38.11%
Intervallo 1D:
$14.14
$15.18
Intervallo di 1 settimana:
$14.13
$15.47
Portata 52W:
$12.04
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
Nome
Myriad Genetics Inc
Settore
Industria
Telefono
801-584-3600
Indirizzo
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Confronta MYGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
14.18 | 1.29B | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
532.55 | 203.70B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.23 | 151.18B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
135.37 | 38.62B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
452.77 | 37.07B | 3.90B | 887.87M | 808.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
191.04 | 33.64B | 15.41B | 1.37B | 2.11B | 7.50 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-12 | Iniziato | Craig Hallum | Buy |
| 2024-12-10 | Iniziato | UBS | Neutral |
| 2024-12-09 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Underperform |
| 2024-05-08 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Ripresa | Piper Sandler | Neutral |
| 2023-12-19 | Iniziato | Wells Fargo | Equal Weight |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Underweight |
| 2023-05-23 | Aggiornamento | Goldman | Sell → Buy |
| 2023-01-18 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Iniziato | Stephens | Equal-Weight |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Sell |
| 2019-09-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Downgrade | Needham | Strong Buy → Hold |
| 2019-07-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2019-03-12 | Reiterato | Needham | Strong Buy |
| 2019-01-03 | Iniziato | Needham | Strong Buy |
| 2018-11-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Iniziato | Goldman | Sell |
| 2018-01-22 | Reiterato | Barclays | Equal Weight |
| 2018-01-05 | Iniziato | BTIG Research | Buy |
| 2017-10-02 | Ripresa | Leerink Partners | Mkt Perform |
| 2017-08-09 | Reiterato | Barclays | Equal Weight |
| 2017-02-08 | Aggiornamento | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Iniziato | Deutsche Bank | Sell |
| 2016-10-10 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
Mostra tutto
Myriad Genetics Inc Borsa (MYGN) Ultime notizie
Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay - MSN
Peregrine Capital Management LLC Boosts Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics Included in Forbes America’s Best Employers 2025 List - GlobeNewswire
This Healthcare Giant's Employee Satisfaction Rate Crushes Industry Average by 27% - StockTitan
Myriad Genetics (MYGN) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025 - GlobeNewswire
Pancreatic Cancer Diagnostic Market to Reach $3.2 billion, Globally, by 2035 at 5.9% CAGR: Allied Market Research - GlobeNewswire Inc.
Myriad Genetics Sets Stage for Major Q4 Financial Reveal: 3 Key Investor Conferences Follow - StockTitan
Myriad Genetics (NASDAQ:MYGN) Trading 8.3% HigherHere's What Happened - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Earns Buy Rating from Analysts at Craig Hallum - MarketBeat
Myriad Genetics secures patents for cancer MRD tests - MSN
Insiders Sold US$6.5m Of Myriad Genetics Stock Possibly Sending Warning Sign - Simply Wall St
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Genomic Biomarker Market Projected To Witness Substantial Growth, 2025-2032: Myriad Genetics, Inc., Eurofins - EIN News
PARP Inhibitor Biomarkers Market Top Players- Myriad Genetics, - openPR
Expert Outlook: Myriad Genetics Through The Eyes Of 8 Analysts - Benzinga
Craig-Hallum initiates Myriad Genetics stock with a Buy rating By Investing.com - Investing.com South Africa
MYGN Stock Might Rise on Collaboration With CancerCARE - MSN
Jennison Associates LLC Raises Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics, INTERLINK Partner To Enhance Access To Hereditary Cancer Testing - Nasdaq
Myriad Genetics and CancerCARE for Life Announce Agreement - GlobeNewswire
Major Healthcare Partnership: Myriad's Advanced Cancer Risk Test Now Available to Million-Plus Patients - StockTitan
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay - GlobeNewswire
Predictive Genetic Counselling Market Size, Trends, - openPR
Myriad Genetics and Lumea Collaborate to Enhance Access to - GlobeNewswire
Myriad Genetics Get 2 Patents for Molecular Residual Disease Assay -February 05, 2025 at 05:41 pm EST - Marketscreener.com
Myriad Genetics secures patents for cancer MRD tests By Investing.com - Investing.com South Africa
Myriad Genetics Announces Two New Patents Granted For Its Molecular Residual Disease (MRD) Assay - Marketscreener.com
Myriad Genetics Partners With Lumea To Integrate Prolaris And MyRisk Tests Into BxLink Platform - Nasdaq
Myriad Genetics and Lumea Inc. Announce Integration of Advanced Molecular Diagnostic Tests into Digital Pathology Platform BxLink - Nasdaq
Lumea and Myriad Genetics Collaborate to Enhance Access to Biomarker and Hereditary Cancer Tests in BxLink - EIN News
Pancreatic Cancer Market Size USD 5.7 Billion, Opportunities, - openPR
Blue Trust Inc. Boosts Stock Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Piper Sandler Cuts Myriad Genetics (NASDAQ:MYGN) Price Target to $14.00 - MarketBeat
Fifth Third Bancorp Sells 23,296 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Sold by Nisa Investment Advisors LLC - Defense World
Piper Sandler Issues Pessimistic Forecast for Myriad Genetics (NASDAQ:MYGN) Stock Price - Defense World
Myriad Genetics (NASDAQ:MYGN) Price Target Cut to $18.00 by Analysts at The Goldman Sachs Group - MarketBeat
Myriad Genetics Unveils Award-Winning Research on Early Prenatal Screening Technology at SMFM Conference - Nasdaq
Myriad Genetics Unveils Groundbreaking Eight Weeks’ - GlobeNewswire
Revolutionary Prenatal Test Gives Parents Answers 2 Weeks Earlier Than Ever Before - StockTitan
DNA Diagnostics Market Booming Demand: Growth Trends, Share, - openPR
Myriad Genetics Inc Azioni (MYGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.06%
3.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):